http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
한국인 크론병의 Infliximab 유지치료 시 Infliximab 단독 투여와 Infliximab과 Azathioprine 병합 투여 비교
원현선 ( Hyun Sun Won ),박동일 ( Dong Il Park ),전창욱 ( Chang Uk Chon ),석효선 ( Hyo Sun Seok ),김태완 ( Tae Wan Kim ),허운제 ( Woon Je Heo ),이창균 ( Chang Kyun Lee ),은창수 ( Chang Soo Eun ),한동수 ( Dong Soo Han ),이석호 ( Suc 대한장연구학회 2011 Intestinal Research Vol.9 No.3
Background/Aims: The benefits and risks of concomitant immunomodulators with infliximab maintenance therapy in patients with luminal Crohn`s disease (CD) have not been adequately evaluated. We studied the influence of immunomodulator discontinuation in patients in remission with infliximab therapy through a restrospective case- control study. Methods: Medical records of 37 patients with luminal CD who received infliximab at four medical centers were retrospectively analyzed. We compared clinical and follow-up data of patients who were treated with infliximab alone with that of patients with combination therapy. Results: Among 37 patients, 31 (83.7%) were treated with infliximab plus azathioprine and six (16.2%) were treated with infliximab alone. Of the 31 patients receiving combination maintenance therapy, 26 (83.9%) were in complete remission after 12 months, as compared with five of six patients (83.3%) receiving infliximab alone. No significant difference was observed in remission rate between two groups (P=0.735). In total, 16.1% of patients in combination therapy and 16.7% in infliximab alone group reported side effects (P=1.000), but serious adverse events such as reactivation of tuberculosis were noted in only one patient in combination therapy group. Conclusions: Concomitant immunomodulators did not improve efficacy in patients with luminal CD who received scheduled infliximab maintenance. (Intest Res 2011;9:189-195)